Publications by authors named "Katia Fiaschetti-Egli"
Metabolic dysfunction-associated steatohepatitis (MASH) is a severe liver disease characterized by lipid accumulation, inflammation and fibrosis. The development of MASH therapies has been hindered by the lack of human translational models and limitations of analysis techniques for fibrosis. The MASH three-dimensional (3D) InSight™ human liver microtissue (hLiMT) model recapitulates pathophysiological features of the disease.
View Article and Find Full Text PDFArticle Synopsis
- Non-alcoholic steatohepatitis (NASH) is a serious liver disease that causes fat buildup, inflammation, and fibrosis, but currently has no approved treatment.
- Researchers developed a 3D microtissue model using human liver cells that mimics NASH, showing key disease features like increased triglycerides and inflammation within 10 days.
- This model allows for the testing of potential anti-NASH drugs, revealing their effectiveness and changing gene expression patterns, making it a valuable tool for drug discovery and understanding NASH's complexities.